Eric Raabe, MD, PhD

Primary Academic Title

Associate Professor of Oncology

Background

Centers and Institutes

• Johns Hopkins Children's Center
• Pediatric Oncology Program
• Sidney Kimmel Comprehensive Cancer Center

Recent News Articles and Media Coverage

• Common Genetic Pathway Could be Conduit to Pediatric Tumor Treatment, Johns Hopkins News Room(November 6th, 2013)
• Going After the Big Bad Tumor, Johns Hopkins Childrens Center( June 11th, 2013)
• Stem Cells May Speed Up Screening of Drugs for Rare Cancers, Johns Hopkins Medicine (August 1, 2016)
• Pediatric Brain Cancer: Julian’s Story | Johns Hopkins Medicine(August 8th, 2020)
• New Funding to Fight Childhood Cancer | Johns Hopkins Medicine(November 9th, 2023)

Additional Academic Titles

Associate Professor of Pathology

Research Interests

Developing novel metabolic-based therapies to disrupt MYC-driven tumors; Disrupting the LIN28 pathway in brain tumors; Targeting stem cell factors and their downstream effectors in malignancy; Specifically in brain tumors; Using neural stem cells to create genetically accurate models of aggressive brain tumors

Lab Website

Eberhart, Rodriguez and Raabe Lab - Lab Website

• Dr. Raabe currently has a research group composed of research assistants, graduate students, and post-doctoral fellows. He continues to work closely with Dr. Charles Eberhart, who is a neuro-pathologist and core collaborator.

Research Summary

Dr. Raabe’s research focuses on translational neuro-oncology, with the overall goal being to develop new therapeutics for poor prognosis brain tumors. Dr. Raabe’s expertise is in stem cell biology, developmental biology and pre-clinical therapeutics. He has generated one of a handful of human diffuse intrinsic pontine glioma cell lines that form xenografts with high fidelity to the primary tumor and retain the H3F3A K27M mutation. He has expertise in targeting stem cell factors in aggressive brain tumors in vivo and in vitro. Dr. Raabe has developed normal human and mouse neural stem cells for use as genetically accurate gain-of-function models for high-risk brain tumors.

Google Scholar

https://scholar.google.com/citations?user=VINW8PwAAAAJ&hl=en

PubMed

http://www.ncbi.nlm.nih.gov/sites/myncbi/eric.raabe.1/bibliography/40141363/public/

Selected Publications

• Hanaford AR, Archer TC, Price A, Kahlert UD, Maciaczyk J, Nikkhah G, Kim JW, Ehrenberger T, Clemons PA, Dancik V, Seashore-Ludlow B, Viswanathan V, Stewart ML, Rees M, Shamji AF, Schreiber SL, Fraenkel E, Pomeroy SL, Mesirov JP, Tamayo P, Eberhart CG*, Raabe EH*. DiSCoVERing innovative therapies for rare tumors: combining genetically accurate disease models with in silico analysis to identify novel therapeutic targets. Clin Cancer Res. 2016 Mar 24. PMID: 27012813. * Co-corresponding author.

• Kaur H, Ali SZ, Huey L, Hutt-Cabezas M, Taylor I, Mao XG, Weingart M, Chu Q, Rodriguez FJ, Eberhart CG, Raabe EH. The transcriptional modulator HMGA2 promotes stemness and tumorigenicity in glioblastoma. Cancer Lett. 2016 Jul 10; 377(1):55-64. doi: 10.1016/j.canlet.2016.04.020. Epub 2016 Apr 18. PMID: 27102002

• Mao, XG, Hutt-Cabezas, M, Orr, BA, Weingart, M, Taylor I, Rajan K, Odia Y, Kahlert U, Maciaczyk J, Nikkhah G, Eberhart CG*, Raabe EH*. LIN28A facilitates the transformation of human neural stem cells and promotes glioblastoma tumor formation by enacting a pro-invasive genetic program. Oncotarget. 2013 Jul;4(7):1050-64. PMCID 3759665 * Co-corresponding author.

• Raabe, E.H., Lim, K.S., Kim, JM., Meeker, A., Mao, XG., Nikkhah, G., Macizczyk, J., Kahlert, U., Jain, D., Bar, E., Cohen, KJ, Eberhart CG. "BRAF Activation Induces Transformation and then Senescence in Human Neural Stem Cells: A Pilocytic Astrocytoma Model." Clinical Cancer Research, (2011) Jun 1;17(11):3590-9. PMCID: PMC4086658

• Weingart MF, Roth J, Hutt-Cabezas M , Busse T , Kaur H, Price A, Maynard R, Rubens J, Taylor I , Mao XG, Xu J, Kuwahara Y, Allen SJ , Erdreich-Epstein A, Weissman BE , Orr BA , Eberhart CG, Biegel J, Raabe EH. Disrupting LIN28 in atypical teratoid rhabdoid tumors reveals the importance of the mitogen activated protein kinase pathway as a therapeutic target. Oncotarget, 2015 Feb 20;6(5):3165-77. PMCID: PMC4413645

Honors

• Francis Schwentker Award for Excellence in Research by Pediatrics House Staff and Fellows, Johns Hopkins Hospital, 5/1/11
• Award Winner, St. Baldrick's Fellowship, 7/1/08
• Alpha Omega Alpha, University of Cincinnati College of Medicine, 10/1/02

Lectures & Presentations

Francis Schwentker Address, Pediatrics Grand Round, Johns Hopkins Children's Center, Baltimore, MD, 5/1/11

Graduate Program Affiliations

Pathobiology Graduate Program

Memberships

• American Association for Cancer Research
• Children's Oncology Group
• Sigma Xi
• Society for Neuro-oncology